Overview

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Study evaluating SOM230 in patients with metastatic carcinoid tumors
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Pasireotide